SCHEMBL19084599

SCHEMBL19084599

Cc1nn2c(=O)cc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1-c1ccc(Cl)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 10/20 0.52
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ARF6 P62330 1/20 0.38
NPBWR1 P48145 1/20 0.37
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
MCL1 Q07820 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
GCGR P47871 1/20 0.36
MAPK14 Q16539 1/20 0.36
CDC7 O00311 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084648 0.87 PSD (0.53) PSDADORA2AADORA1ARF6MAPT
SCHEMBL13516359 0.87 PSD (0.48) PSDADORA2AADORA1ARF6NPBWR1
SCHEMBL19084608 0.87 PSD (0.48) PSDADORA2AADORA1ARF6MAPT
SCHEMBL19084536 0.83 PSD (0.48) PSDADORA2AADORA1NPBWR1MAPT
SCHEMBL10276296 0.82 PSD (0.52) PSDADORA2AADORA1ARF6NPBWR1
SCHEMBL19084684 0.82 PSD (0.53) PSDADORA2AADORA1ARF6MAPT
SCHEMBL19084553 0.81 MAPT (0.54) PSDADORA2AADORA1NPBWR1MAPT
SCHEMBL19084664 0.81 PSD (0.51) PSDADORA2AADORA1MAPTALDH1A1
SCHEMBL19084552 0.80 PSD (0.53) PSDADORA2AADORA1MAPTALDH1A1
SCHEMBL19084535 0.79 PSD (0.54) PSDARF6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ADORA2A 4263/4885ADORA1 4220/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ADORA2A 4263/4885ADORA1 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.